Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 16/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.69 |
| ▸ | ARRB1 | P49407 | 6/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399328 | 1.00 | OPRM1 (0.69) | OPRM1OPRD1OPRK1ARRB1SLC6A2 | |
| SCHEMBL22662418 | 1.00 | OPRM1 (0.69) | OPRM1OPRD1OPRK1ARRB1SLC6A2 | |
| Hydrochloric Acid SCHEMBL30515580 | 0.99 | OPRM1 (0.68) | OPRM1OPRD1OPRK1ARRB1SLC6A2 | |
| Hydrochloric Acid SCHEMBL20399489 | 0.99 | OPRM1 (0.68) | OPRM1OPRD1OPRK1ARRB1SLC6A2 | |
| SCHEMBL23191775 | 0.89 | OPRM1 (0.55) | OPRM1OPRD1OPRK1ARRB1SLC6A2 | |
| SCHEMBL22662480 | 0.84 | OPRM1 (0.54) | OPRM1OPRD1OPRK1ARRB1SLC6A2 | |
| SCHEMBL3239924 | 0.82 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ARRB1SLC6A2 | |
| SCHEMBL3243590 | 0.82 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ARRB1SLC6A2 | |
| SCHEMBL3238503 | 0.82 | OPRM1 (1.00) | OPRM1OPRD1OPRK1ARRB1SLC6A2 | |
| SCHEMBL24969483 | 0.80 | OPRD1 (0.68) | OPRM1OPRD1OPRK1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3570838-B1 | SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY INC (US) | 2024-06-05 | — | — | EP | claimed |
| US-20240043387-A1 | SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY INC (US) | 2024-02-08 | — | — | US | claimed |
| CN-116751156-A | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using the same | 梅比斯发现公司 | 2023-09-15 | — | — | CN | claimed |
| US-20250282731-A1 | SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-12162837-B2 | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240043387-A1 | SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY INC (US) | 2024-02-08 | — | — | US | disclosed |
| CN-116751156-A | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using the same | 梅比斯发现公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-110392571-B | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using the same | 梅比斯发现公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11319290-B2 | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043387-A1 | SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME | ALKBH5, ALKBH2, ALKBH3 | OPRM1 222/4885OPRD1 388/4885OPRK1 13/4885 |
| US-20250282731-A1 | SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME | ALKBH5, ALKBH2, ALKBH3 | OPRM1 222/4885OPRD1 388/4885OPRK1 13/4885 |
| US-12162837-B2 | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | ALKBH5, ALKBH2, ALKBH3 | OPRM1 222/4885OPRD1 388/4885OPRK1 13/4885 |
| US-11319290-B2 | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | ALKBH5, ALKBH2, ALKBH3 | OPRM1 222/4885OPRD1 388/4885OPRK1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.